Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA clears AI software for detecting untreated pulmonary hypertension in 12-lead ECGs

24 August 2026 · By · Wire by Fusion42

Published

24 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at cardiovascularbusiness.com →

◆ Verified

Fusion42 · 24 August 2026 · Fusion42 review

Tempus AI has received FDA clearance for Tempus ECG-PH, an AI-powered software that detects signs of pulmonary hypertension using 12-lead ECGs, aimed to assist clinicians in earlier risk identification but not for standalone diagnosis.

This Wire brief sits within Fusion42's coverage of Medtech, and 4 sources have reported it between 24 Aug 2026 and 28 Aug 2026.

◆ ◆ The Wire takeaway

Medtech founders in cardiovascular AI now have a clearer market path in the US after this clearance. You should prioritise clinical partnerships to integrate your AI tools with diagnostic workflows.

◆ Coverage

4 sources · first reported 24 Aug 2026 · latest 28 Aug 2026

◆ Related on Wire

◆ Topics

Medtechfda-clearanceai-healthpulmonary-hypertensionecgtempus-ai